| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Molecular diagnostics | | | | | | 2.6 | | |
| Genetic analysis | | | | | | 44.9 | | |
| Sequenom Laboratories | | | | | 8.3 | | | |
| Other | | | | | 47.6 | | | |
| Total revenues [+] | 128.3 | 151.6 | 119.6 | 46.5 | 55.9 | 47.5 | 37.9 | 47.1 |
| Products | 8.4 | 3.0 | 0.8 | | 47.6 | 44.9 | 37.8 | |
| Services | 119.8 | 148.6 | 118.7 | 46.5 | 8.3 | 2.6 | 0.1 | |
| Net interest income | | | | | | | -0.3 | |
| Revenue growth | -15.4% | 26.8% | 157.3% | -16.9% | 17.8% | 25.3% | -19.7% | 15.0% |
| Cost of goods sold [+] | 67.0 | 83.5 | 87.3 | 47.3 | 26.4 | 22.3 | 14.6 | 4.5 |
| Cost of services | | | | | 10.0 | 4.0 | 0.4 | |
| Gross profit | 61.3 | 68.1 | 32.3 | -0.8 | 29.5 | 25.2 | 23.3 | 42.7 |
| Gross margin | 47.8% | 44.9% | 27.0% | -1.8% | 52.8% | 53.1% | 61.5% | 90.5% |
| Selling, general and administrative [+] | 67.5 | 77.7 | 90.1 | 73.6 | 50.4 | 47.4 | 55.0 | 42.7 |
| Sales and marketing | 34.7 | 30.8 | 37.6 | 33.8 | 28.2 | 25.1 | 26.8 | 24.3 |
| General and administrative | 32.7 | 46.9 | 52.5 | 39.8 | 22.2 | 22.3 | 28.1 | 18.4 |
| Research and development | 22.8 | 25.0 | 38.7 | 40.2 | 53.3 | 43.4 | 37.5 | 27.5 |
| Other operating expenses | -21.8 | -22.9 | | | | 55.4 | | 15.1 |
| EBITDA [+] | 2.9 | 0.4 | -82.4 | -104.2 | -67.1 | -115.4 | -63.9 | -39.7 |
| EBITDA growth | 571.0% | -100.5% | -20.9% | 55.3% | -41.9% | 80.5% | 60.9% | 92.6% |
| EBITDA margin | 2.3% | 0.3% | -69.0% | -224.2% | -120.0% | -243.2% | -168.9% | -84.3% |
| Depreciation and amortization | 10.1 | 12.2 | 14.2 | 10.5 | 7.1 | 5.6 | 5.2 | 2.9 |
| EBIT [+] | -7.2 | -11.8 | -96.6 | -114.6 | -74.2 | -121.0 | -69.1 | -42.6 |
| EBIT growth | -38.8% | -87.8% | -15.7% | 54.5% | -38.7% | 75.1% | 62.2% | 88.8% |
| EBIT margin | -5.6% | -7.8% | -80.8% | -246.8% | -132.7% | -255.0% | -182.6% | -90.4% |
| Non-recurring items | 0.7 | 1.9 | 5.8 | | | | 1.6 | |
| Interest expense, net [+] | 8.0 | 8.1 | 8.4 | -0.1 | 0.3 | 0.0 | -0.4 | -1.5 |
| Interest expense | 8.1 | 8.2 | 8.6 | | 0.3 | 0.0 | | 0.1 |
| Interest income | 0.1 | 0.1 | 0.1 | 0.1 | | | 0.4 | 1.6 |
| Other income (expense), net [+] | -0.2 | -0.2 | -0.1 | -3.4 | 0.5 | 0.2 | -0.6 | -2.8 |
| Unrealized gain (loss) on marketable securities | | | | | | | -1.9 | |
| Litigation settlement | | | | | | 55.4 | | |
| Other | -0.2 | -0.2 | -0.1 | 0.0 | 0.5 | 0.2 | 1.6 | |
| Pre-tax income | -16.1 | -22.0 | -110.9 | -118.0 | -74.0 | -120.9 | -70.9 | -43.9 |
| Income taxes | 0.2 | -7.7 | -1.4 | -0.7 | 0.1 | 0.0 | 0.1 | 0.2 |
| Tax rate | | 34.8% | 1.2% | 0.6% | | 0.0% | | |
| Earnings from continuing ops | -16.3 | -14.4 | -109.6 | -117.3 | -74.1 | -120.8 | -71.0 | -44.2 |
| Earnings from discontinued ops | | 15.4 | | 0.3 | | | | |
| Net income | -16.3 | 1.0 | -107.4 | -117.0 | -74.1 | -120.8 | -71.0 | -44.2 |
| Net margin | -12.7% | 0.7% | -89.8% | -251.9% | -132.6% | -254.6% | -187.5% | -93.6% |
| |
| Basic EPS [+] | ($0.14) | ($0.12) | ($0.95) | ($1.03) | ($0.75) | ($1.69) | ($1.16) | ($0.83) |
| Growth | 12.3% | -87.0% | -8.0% | 38.0% | -55.6% | 45.2% | 39.7% | 46.9% |
| Diluted EPS [+] | ($0.14) | ($0.12) | ($0.95) | ($1.03) | ($0.75) | ($1.69) | ($1.16) | ($0.83) |
| Growth | 12.3% | -87.0% | -8.0% | 38.0% | -55.6% | 45.2% | 39.7% | 46.9% |
| |
| Shares outstanding (basic) [+] | 118.2 | 116.7 | 115.4 | 113.6 | 99.1 | 71.7 | 61.2 | 53.1 |
| Growth | 1.3% | 1.2% | 1.5% | 14.6% | 38.3% | 17.2% | 15.1% | 36.7% |
| Shares outstanding (diluted) [+] | 118.2 | 116.7 | 115.4 | 113.6 | 99.1 | 71.7 | 61.2 | 53.1 |
| Growth | 1.3% | 1.2% | 1.5% | 14.6% | 38.3% | 17.2% | 15.1% | 36.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |